• 09:00, 26 Mar 19 - 18:00, 26 Mar 19
  • The Cameron Fund, London
  • Print page

The Economist Events' Antimicrobial Resistance (AMR) Summit taking place in London on March 26th, 2019. The event will gather 120+ health policy leaders, academics and other experts across the industry for a frank discussion to catalyse progress in bringing AMR under control before it is too late.

Questions we will ask:

- How can new-market entry awards circumvent “blind spots” in conventional funding mechanisms and incentivise R&D?
- Does the drug-approval process need a fundamental re-think?
- How can surveillance of the supply chain be improved to stop substandard medicines reaching the market?
- There are currently few licensed vaccines for the bacteria that are considered urgent AMR threats. How can we change this?
- How can the transition from industry’s bottom-line reliance on overselling antibiotics be managed?

Confirmed speakers include:
- Marc Sprenger, director, antimicrobial resistance secretariat, World Health Organisation
- David Heymann, head, centre for global health security, Chatham House
- Jean Patel, science team lead, antibiotic resistance co-ordination and strategy, CDC
- Mark Pearson, deputy director, Directorate for employment, labour and social affairs, OECD
- Kevin Outterson, executive director and principal investigator, Carb X
- Nina Grundmann, senior manager, global health and economic policy, International - Federation of Pharmaceutical Manufacturers and Associations
- Martin Seychell, deputy director general, Directorate-General for Health and Food Safety (DG SANTE)
- Umang Vohra, global chief executive, Cipla
- Keiji Fukuda, director and clinical professor, school of public health, Li Ka Shing faculty of medicine, The University of Hong Kong


£671.25 Academic/Government/Public Sector/Charity/NGO rate

£695 Earlybird rate

£716 The Economist Subscriber Rate

£895 Standard rate